Director – Dr. Kevin K . W. Wang, Ph.D.
Director – Program for Neurotrauma, Neuroproteomics & Biomarkers Research (NNBR)
Associate Professor, Departments of Emergency, Psychiatry & Neuroscience and Physiological Sciences
McKnight Brain Institute of the University of Florida, Gainesville, FL 32611, USA
Health Research Scientist at Malcom Randall VA Medical Center (Gainesville, FL)
Council member, Chinese Neurotrauma Scholar Association
2017 Congress Chair, Academy of Multidisciplinary Neurotraumatology
Member of Development Committee, National Neurotrauma Society (USA)
NNBR Website: http://nnbr.emergency.med.ufl.edu/
Research Gate: https://www.researchgate.net/profile/Kevin_Wang6
Dr. Wang obtained his Ph.D. in Pharmaceutical Sciences with Distinction from the University of British Columbia in Vancouver in 1989. He is internationally recognized for his original contributions to the fields of CNS disorders-linked proteolytic enzymes, neuroproteomics and disease biomarker discovery. He joined Parke-Davis Pharmaceutical Research (Ann Arbor, MI) in 1991, and following the company’s merger with Pfizer Inc. (2000), he became Group Leader of CNS Therapeutics/CNS new targets team. He also co-chaired the Far East Scientific Opportunity Team. In 2002, he became Associate Professor of Psychiatry at the University of Florida (Gainesville, FL), Associate Director of the Center for Traumatic Brain Injury Studies and Director of the Center of Neuroproteomics and Biomarkers Research. In 2002, he is a Founder of biotechnology company Banyan Biomarkers Inc. (Alachua, Florida). In 2007, he transitioned to Banyan as full-time Chief Scientific Officer and the Center Director of the Center of Innovative Research. . Dr. Wang has contributed significantly to the discovery, sensitive sandwich ELISA development of two acute TBI protein biomarkers (UCH-L1 and GFAP-BDP) and their diagnostic utility characterization in several animal and human TBI spectrum studies. This TBI biomarker tandem is now in pivotal study for FDA approval as a new first-in-class in vitro diagnostic (IVD) test for mild-moderate TBI (ALERT Trial). In 2011, he rejoined the University of Florida McKnight Brain Institute as Executive Director of the Center of Neuroproteomics and Biomarkers Research /Chief – Translational Research to direct a vigorous basic and translational research program. He is also Chair Professor of the Graduate Institute of Medical Science/Department of Surgery, Taipei Medical University (Taipei), as well as Adjunct Research Professor of Neurology at the SUNY-Downstate (New York).
Dr. Wang is also Principal Investigator of VA Merit Award and is Health Research Scientist at Malcom Randall VA Medical Center (Gainesville, FL) where he focuses on conducting/advancing the Veterans-relevant medical research, as well as improving Veterans patient care, management and treatment options.
His research also expanded to proteomic technologies to psychiatric disorders because neuronal injury biomarkers are also highly relevant to psychiatric diseases such as substance abuse and schizophrenia. His laboratory is developing animal model for substance abuse (ecstasy (MDMA), methamphetamine and alcohol abuse, bath salts/designer psychostimulants). In parallel, his group is employing an integrated proteomics-based approach to discover novel biomarkers for these neurological and psychiatric diseases. These technologies include: (1) 2D gel electrophoresis-MALDI-TOF, (2) 2D-LC-MS/MS, (3) CAX-PAGE RPLC-MS/MS, and (4) monoclonal antibody array.
Dr. Wang published more than 220 peer-reviewed papers, reviews and book chapters and co-authored eight US patents. He co-edited four books on proteases, neuroproteomics and biomarkers for CNS disorders. He also serves on five international journal’s Editorial Board. Dr. Wang was Past President and is current Council member of the National Neurotrauma Society (USA).
His research interests include neuro-proteomics, CNS Injury, neurodegeneration, substance abuse research (methamphetamine, MDMA, nath salts), protein post-translational modification (proteases / protein kinases), biomarkers discovery and assay development, diagnostics, therapeutic development and theranostics.